Free Trial

Cullinan Therapeutics (CGEM) Stock Price, News & Analysis

-0.49 (-2.12%)
(As of 05/23/2024 ET)
Today's Range
50-Day Range
52-Week Range
590,035 shs
Average Volume
633,972 shs
Market Capitalization
$975.54 million
P/E Ratio
Dividend Yield
Price Target

Cullinan Therapeutics MarketRank™ Stock Analysis

Analyst Rating
3.00 Rating Score
41.3% Upside
$32.00 Price Target
Short Interest
10.23% of Float Sold Short
Dividend Strength
News Sentiment
0.40mentions of Cullinan Therapeutics in the last 14 days
Based on 16 Articles This Week
Insider Trading
Selling Shares
$1.63 M Sold Last Quarter
Proj. Earnings Growth
From ($3.02) to ($3.07) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.84 out of 5 stars

Medical Sector

382nd out of 915 stocks

Biological Products, Except Diagnostic Industry

58th out of 149 stocks

CGEM stock logo

About Cullinan Therapeutics Stock (NASDAQ:CGEM)

Cullinan Therapeutics, Inc., a biopharmaceutical company, focuses on developing oncology therapies for cancer patients in the United States. The company's lead program comprises CLN-619, a monoclonal antibody that is in Phase I clinical trial for the treatment of solid tumors. Its development portfolio also includes CLN-049, a humanized bispecific antibody that is in Phase I clinical trial for the treatment of acute myeloid leukemia or myelodysplastic syndrome; CLN-418, a human bispecific immune activator that is in Phase 1 clinical trial for the treatment of multiple solid tumors; and Zipalertinib, a bioavailable small-molecule for treating patients with non-small cell lung cancer. In addition, the company's development products comprise CLN-617, a fusion protein for the treatment of solid tumors; and CLN-978, a T cell engaging antibody for the treatment relapsed/refractory B-cell non-Hodgkin lymphoma. It has license and collaboration agreement with Adimab, LLC to discover and/or optimize antibodies; Harbour BioMed US Inc. for the development, manufacturing, and commercialization of CLN-418; and co-development agreement with Taiho Pharmaceutical Co., Ltd to develop Zipalertinib. Cullinan Therapeutics, Inc. was formerly known as Cullinan Oncology, Inc. and changed its name to Cullinan Therapeutics, Inc. in April 2024. Cullinan Therapeutics, Inc. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CGEM Stock Price History

CGEM Stock News Headlines

Cullinan changes name, pivots to autoimmune disease
See More Headlines
Receive CGEM Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cullinan Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
7 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$18.94 million
Book Value
$9.88 per share


Free Float
Market Cap
$975.54 million
7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors Cover

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

  • Mr. Nadim AhmedMr. Nadim Ahmed (Age 56)
    President, CEO & Director
    Comp: $1.16M
  • Dr. Jeffrey Jones M.B.A. (Age 53)
    M.D., M.P.H., Chief Medical Officer
    Comp: $780.32k
  • Dr. Patrick A. Baeuerle Ph.D. (Age 66)
    Co-Founder, Chief Scientific Advisor & Chairman of Scientific Advisory Board
    Comp: $763.73k
  • Ms. Mary Kay Fenton (Age 60)
    Chief Financial Officer
  • Dr. Jennifer Michaelson Ph.D. (Age 57)
    Chief Scientific Officer
  • Ms. Jacquelyn L. Sumer J.D. (Age 46)
    Chief Legal Officer, Chief Compliance Officer & Corporate Secretary
  • Ms. Rose Weldon
    Senior Vice President of Communications
  • Mr. Steve Andre
    Chief Human Resources Officer
  • Dr. Corinne Savill Ph.D. (Age 65)
    Chief Business Officer
  • Mr. Kevin A. Johnston
    Chief Technical Operations Officer

CGEM Stock Analysis - Frequently Asked Questions

Should I buy or sell Cullinan Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cullinan Therapeutics in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEM shares.
View CGEM analyst ratings
or view top-rated stocks.

What is Cullinan Therapeutics' stock price target for 2024?

7 Wall Street analysts have issued 1-year price objectives for Cullinan Therapeutics' shares. Their CGEM share price targets range from $26.00 to $40.00. On average, they predict the company's stock price to reach $32.00 in the next twelve months. This suggests a possible upside of 41.3% from the stock's current price.
View analysts price targets for CGEM
or view top-rated stocks among Wall Street analysts.

How have CGEM shares performed in 2024?

Cullinan Therapeutics' stock was trading at $10.19 at the beginning of the year. Since then, CGEM stock has increased by 122.3% and is now trading at $22.65.
View the best growth stocks for 2024 here

When is Cullinan Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our CGEM earnings forecast

How were Cullinan Therapeutics' earnings last quarter?

Cullinan Therapeutics, Inc. (NASDAQ:CGEM) released its quarterly earnings results on Thursday, March, 14th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.96) by $0.42.

What ETFs hold Cullinan Therapeutics' stock?
When did Cullinan Therapeutics IPO?

Cullinan Therapeutics (CGEM) raised $149 million in an IPO on Friday, January 8th 2021. The company issued 8,300,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley, SVB Leerink and Evercore ISI served as the underwriters for the IPO and H.C. Wainwright & Co., LLC was co-manager.

Who are Cullinan Therapeutics' major shareholders?

Cullinan Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (4.12%), Affinity Asset Advisors LLC (0.60%), Kennedy Capital Management LLC (0.20%), California State Teachers Retirement System (0.06%), Price T Rowe Associates Inc. MD (0.05%) and Mirae Asset Global Investments Co. Ltd. (0.04%). Insiders that own company stock include Ansbert Gadicke, Bioscience I 2017 Ltd F2, Bvf Partners L P/Il, Corrine Savill, Jeffrey Alan Jones, Jeffrey Trigilio, Jennifer Michaelson, Leigh Zawel, Nadim Ahmed, Oncology Impact Fund LP Ubs and Vision Scs F2.
View institutional ownership trends

How do I buy shares of Cullinan Therapeutics?

Shares of CGEM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGEM) was last updated on 5/24/2024 by Staff

From Our Partners